Propranolol

As a classic β-blocker with over half a century of clinical application, propranolol exerts multiple effects of lowering blood pressure, resisting myocardial ischemia and antiarrhythmia by competitively blocking cardiac β₁ adrenergic receptors to reduce myocardial contractility, slow down heart rate and decrease cardiac output, and meanwhile blocking renal β₂ receptors to inhibit renin release. Its indications cover hypertension, exertional angina, supraventricular tachyarrhythmia, and heart rate control for hyperthyroidism. It can also be used to reduce the long-term mortality of patients with myocardial infarction. It is one of the basic drugs in the cardiovascular field, and its applicable population includes cardiovascular chronic disease patients of different age groups and people receiving symptomatic treatment for related acute diseases.

At present, the global market size of propranolol API is approximately USD 120 million, and the compound annual growth rate from 2023 to 2028 is expected to remain at around 2.8%. The demand growth mainly comes from the popularization of primary-level hypertension prevention and control, the improvement of the diagnosis and treatment rate of thyroid diseases, and the expansion of off-label applications such as migraine prevention. China is the core supplier of propranolol API in the world, with its production capacity accounting for more than 65% of the global total. The domestic market has formed a pattern dominated by generic drugs. After the implementation of centralized drug procurement, the terminal price of preparations has dropped by more than 70%, further promoting the concentration of upstream API demand to compliant production capacity.

The original developer of propranolol is AstraZeneca, with the original brand name "Xin De'an" (Inderal). The core compound patent expired globally in 1986. Currently, commonly used clinical dosage forms include 10mg and 40mg common tablets, as well as 80mg and 160mg sustained-release capsules. The original preparation has been included in the FDA Reference Listed Drug Catalog and China's *Catalog of Reference Preparations for Chemical Drugs*. According to the domestic API registration platform, 12 enterprises have obtained A-status registration numbers for their propranolol APIs, and more than 30 enterprises have obtained marketing approvals for propranolol common tablets and sustained-release preparations. (Data as of October 2024, please refer to the official website of CDE for the latest information)

CATO provides a full set of impurity reference standards for propranolol API. The products cover all categories including pharmacopeial impurities, degradation impurities and process impurities, and meet the compliance requirements of multiple regulations such as the Chinese Pharmacopoeia and FDA. Most products are in stock. In-stock orders placed before 16:00 can be shipped on the same day, which can fully meet various reference standard needs of pharmaceutical enterprises for R&D, quality research and production release.